Dynavax Technologies Co. (NASDAQ:DVAX) Shares Acquired by Public Sector Pension Investment Board

Public Sector Pension Investment Board increased its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 8.7% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 287,958 shares of the biopharmaceutical company’s stock after purchasing an additional 23,012 shares during the quarter. Public Sector Pension Investment Board owned 0.22% of Dynavax Technologies worth $3,234,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in shares of Dynavax Technologies in the 2nd quarter valued at $184,000. Duality Advisers LP purchased a new stake in shares of Dynavax Technologies during the 1st quarter valued at about $227,000. Boston Partners acquired a new position in Dynavax Technologies during the 1st quarter worth approximately $292,000. China Universal Asset Management Co. Ltd. boosted its holdings in Dynavax Technologies by 67.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 10,143 shares during the period. Finally, Evoke Wealth LLC acquired a new stake in Dynavax Technologies in the second quarter valued at approximately $305,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Trading Up 1.4 %

Dynavax Technologies stock opened at $11.00 on Friday. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.15. The firm’s 50-day moving average is $11.07 and its 200-day moving average is $11.43. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The company has a market cap of $1.44 billion, a P/E ratio of 183.33 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same period in the previous year, the firm posted $0.03 earnings per share. On average, equities analysts expect that Dynavax Technologies Co. will post 0.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DVAX. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a report on Wednesday, August 7th. The Goldman Sachs Group decreased their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Dynavax Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $23.67.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.